TGIF2LX1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TGIF2LX1 protein, which is a member of the TGIF (thymine-rich, G-rich, and immunoglobulin-like factors) family. This protein plays a significant role in regulating gene expression and cellular development, particularly in the context of embryonic development and patterning. TGIF2LX1 acts as a transcriptional co-repressor, modulating the activity of various transcription factors by binding to their target genes. Inhibition of TGIF2LX1 is achieved primarily by binding to its critical regions, such as the DNA-binding domain or interaction sites essential for recruiting other proteins involved in transcriptional regulation. By occupying these binding sites, TGIF2LX1 inhibitors effectively disrupt the protein's normal regulatory functions, leading to altered gene expression profiles. Some inhibitors may also function through allosteric mechanisms, binding to regions separate from the active site and inducing conformational changes that diminish the protein's activity. The binding interactions between these inhibitors and TGIF2LX1 are typically stabilized by a range of non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions.
Structurally, TGIF2LX1 inhibitors demonstrate considerable diversity, enabling specific interactions with different regions of the TGIF2LX1 protein. These inhibitors often incorporate functional groups such as hydroxyl, carboxyl, or amine groups, facilitating strong interactions through hydrogen bonding and ionic interactions with key amino acid residues in the protein's binding pockets. Many TGIF2LX1 inhibitors also feature aromatic rings or heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the protein, thereby contributing to the overall stability of the inhibitor-protein complex. The physicochemical properties of TGIF2LX1 inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are meticulously optimized to ensure effective binding and stability in various biological environments. This balance between hydrophilic and hydrophobic regions allows TGIF2LX1 inhibitors to interact selectively with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TGIF2LX1 activity across diverse cellular contexts.
VER TAMBIÉN ....
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | ¥1185.00 ¥1726.00 | 4 | |
Como inhibidor de la cinasa del receptor TGF-β, el LY364947 podría reducir la expresión de TGIF2LX impidiendo la activación de su cascada de señalización. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | ¥2358.00 ¥3971.00 | 3 | |
Este inhibidor selectivo del receptor I de TGF-β puede suprimir potencialmente la expresión de TGIF2LX inhibiendo la activación transcripcional mediada por TGF-β. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | ¥846.00 ¥1692.00 ¥2426.00 ¥7333.00 ¥13809.00 ¥48467.00 ¥88203.00 | 8 | |
RepSox es un inhibidor selectivo del receptor TGF-β que podría disminuir la expresión de TGIF2LX atenuando la señalización de TGF-β. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | ¥1128.00 ¥4603.00 | 6 | |
Esta pequeña molécula puede disminuir indirectamente la expresión de TGIF2LX modulando las respuestas fibrogénicas mediadas por TGF-β. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | ¥19631.00 | ||
La halofuginona inhibe la señalización del TGF-β, lo que podría reducir la expresión de TGIF2LX al alterar su regulación génica descendente. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | ¥338.00 ¥1139.00 ¥3125.00 ¥10819.00 | 2 | |
Tranilast puede inhibir la expresión de TGIF2LX antagonizando el TGF-β y reduciendo su actividad transcripcional relacionada. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | ¥970.00 | 3 | |
Como inhibidor de la cinasa del receptor I del TGF-β, el SD-208 podría regular a la baja la expresión de TGIF2LX bloqueando la vía de señalización del TGF-β. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | ¥3892.00 | ||
EW-7197 inhibe la señalización de TGF-β, lo que podría conducir a una menor expresión de TGIF2LX al interferir con sus mecanismos de inducción. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | ¥982.00 ¥3046.00 | 9 | |
Esta sustancia química puede reducir la expresión de TGIF2LX al inhibir la actividad quinasa del receptor I del TGF-β, bloqueando así su vía de señalización. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | ¥6465.00 | ||
El vactosertib, al inhibir el receptor I del TGF-β, podría disminuir potencialmente la expresión de TGIF2LX mediante la supresión de su vía de señalización. | ||||||